Swiss pharma giant Novartis AG’s (NVS) Biologics License Application for Brolucizumab for the treatment of wet age-related macular degeneration is under FDA review, with a decision expected by October 15, 2019.Wet age-related macular degeneration (AMD), also known as neovascular AMD, or nAMD, is a leading cause of blindness worldwide and a rapidly growing public health concern. As the disease progresses, patients may experience loss of central vision, which in due course may lead to blindness, if left untreated. It is estimated that 20 to 25 million people worldwide are affected by wet AMD. Bayer and Regeneron’s Eylea, and Novartis’ Lucentis are market-leading drugs for wet AMD.If approved Brolucizumab could bring in peak sales of over $1 billion by 2021, according to analysts from GlobalData.NVS closed Friday’s (Sep.27, 2019) trading at $87.40, up 0.60%.